Despite the advent of mAbs (e.g., the anti-CD38 mAbs, bi-specific antibodies) having enhanced the overall survival of MM patients [97], their use has been associated with a higher risk of developing hypogammaglobulinemia and severe infections [98]. The gene discussed is CD38; the disease is Miyoshi myopathy.